Treating female heart failure patients with metoprolol CR/XL

Jalal K. Ghali, Ileana L. Pina, Stephen S. Gottlieb, Prakash C. Deedwania, John C. Wikstrand

Research output: Contribution to journalArticle

Abstract

We examined the effect of metoprolol controlled release/extended release (CR/XL) in 898 female patients participating in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. There was a 21 reduction in the primary end points of total mortality and all-cause hospitalization. There was also a decrease in all-cause (15%), cardiovascular-cause (29%), and heart-failure hospitalization (42%). These data show the therapeutic benefit of beta blocking agents in women with heart failure.

Original languageEnglish (US)
Pages (from-to)29-32
Number of pages4
JournalCardiology Review
Volume19
Issue number12
StatePublished - Oct 2002
Externally publishedYes

Fingerprint

Metoprolol
Heart Failure
Hospitalization
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ghali, J. K., Pina, I. L., Gottlieb, S. S., Deedwania, P. C., & Wikstrand, J. C. (2002). Treating female heart failure patients with metoprolol CR/XL. Cardiology Review, 19(12), 29-32.

Treating female heart failure patients with metoprolol CR/XL. / Ghali, Jalal K.; Pina, Ileana L.; Gottlieb, Stephen S.; Deedwania, Prakash C.; Wikstrand, John C.

In: Cardiology Review, Vol. 19, No. 12, 10.2002, p. 29-32.

Research output: Contribution to journalArticle

Ghali, JK, Pina, IL, Gottlieb, SS, Deedwania, PC & Wikstrand, JC 2002, 'Treating female heart failure patients with metoprolol CR/XL', Cardiology Review, vol. 19, no. 12, pp. 29-32.
Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Treating female heart failure patients with metoprolol CR/XL. Cardiology Review. 2002 Oct;19(12):29-32.
Ghali, Jalal K. ; Pina, Ileana L. ; Gottlieb, Stephen S. ; Deedwania, Prakash C. ; Wikstrand, John C. / Treating female heart failure patients with metoprolol CR/XL. In: Cardiology Review. 2002 ; Vol. 19, No. 12. pp. 29-32.
@article{6523eac7a4804cff8dc9bb7d227e56c7,
title = "Treating female heart failure patients with metoprolol CR/XL",
abstract = "We examined the effect of metoprolol controlled release/extended release (CR/XL) in 898 female patients participating in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. There was a 21 reduction in the primary end points of total mortality and all-cause hospitalization. There was also a decrease in all-cause (15{\%}), cardiovascular-cause (29{\%}), and heart-failure hospitalization (42{\%}). These data show the therapeutic benefit of beta blocking agents in women with heart failure.",
author = "Ghali, {Jalal K.} and Pina, {Ileana L.} and Gottlieb, {Stephen S.} and Deedwania, {Prakash C.} and Wikstrand, {John C.}",
year = "2002",
month = "10",
language = "English (US)",
volume = "19",
pages = "29--32",
journal = "Cardiology Board Review",
issn = "1092-6607",
publisher = "Ascend Media",
number = "12",

}

TY - JOUR

T1 - Treating female heart failure patients with metoprolol CR/XL

AU - Ghali, Jalal K.

AU - Pina, Ileana L.

AU - Gottlieb, Stephen S.

AU - Deedwania, Prakash C.

AU - Wikstrand, John C.

PY - 2002/10

Y1 - 2002/10

N2 - We examined the effect of metoprolol controlled release/extended release (CR/XL) in 898 female patients participating in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. There was a 21 reduction in the primary end points of total mortality and all-cause hospitalization. There was also a decrease in all-cause (15%), cardiovascular-cause (29%), and heart-failure hospitalization (42%). These data show the therapeutic benefit of beta blocking agents in women with heart failure.

AB - We examined the effect of metoprolol controlled release/extended release (CR/XL) in 898 female patients participating in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. There was a 21 reduction in the primary end points of total mortality and all-cause hospitalization. There was also a decrease in all-cause (15%), cardiovascular-cause (29%), and heart-failure hospitalization (42%). These data show the therapeutic benefit of beta blocking agents in women with heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0036772278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036772278&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036772278

VL - 19

SP - 29

EP - 32

JO - Cardiology Board Review

JF - Cardiology Board Review

SN - 1092-6607

IS - 12

ER -